The Finnegan Neonatal Abstinence Scoring System (FNASS) is the standard clinical tool for monitoring infants born to mothers with substance use disorders (primarily opioids). It quantifies the severity of withdrawal symptoms across neurological, metabolic, and gastrointestinal systems to guide pharmacological treatment.